Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - famotidine - tablets - famotidine 40 mg - famotidine - famotidine - treatment of duodenal ulcer, benign gastric ulcer, pathological hypersecretory conditions such as zollinger-ellison syndrome, gastroesophageal reflux disease. prevention of relapses of duodenal ulceration.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - tablets - erythromycin as stearate 250 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - donepezil hydrochloride - tablets - donepezil hydrochloride 5 mg - donepezil - donepezil - treatment of mild to moderately severe alzheimer's dementia.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - donepezil hydrochloride - tablets - donepezil hydrochloride 5 mg - donepezil - donepezil - treatment of mild to moderately severe alzheimer's dementia.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - donepezil hydrochloride - tablets - donepezil hydrochloride 10 mg - donepezil - donepezil - treatment of mild to moderately severe alzheimer's dementia.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - abiraterone acetate - tablets - abiraterone acetate 250 mg - abiraterone - abiraterone acetate is cyp17 inhibitor indicated:- in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.- for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt).

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - donepezil hydrochloride - tablets - donepezil hydrochloride 10 mg - donepezil - treatment of mild to moderately severe alzheimer's dementia.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - lercanidipine hydrochloride - tablets - lercanidipine hydrochloride 10 mg - lercanidipine - mild to moderate essential hypertension.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - lercanidipine hydrochloride - tablets - lercanidipine hydrochloride 20 mg - lercanidipine - mild to moderate essential hypertension.

Izrael - angol - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute c